--(BUSINESS WIRE)-- BioCryst Pharmaceuticals designs, optimizes and develops novel small-molecule pharmaceuticals that block key enzymes involved in infectious diseases, cancer and inflammatory diseases. BioCryst has progressed two novel compounds that are in late-stage pivotal trials; peramivir, a neuraminidase inhibitor for the treatment of influenza, and forodesine, an orally-available purine nucleoside phosphorylase (PNP) inhibitor for cutaneous T-cell lymphoma (CTCL). Additionally, BioCryst has a third product candidate, BCX4208—a next generation PNP inhibitor—in mid-stage trials for the treatment of gout. Utilizing crystallography and structure-based drug design, BioCryst continues to discover additional compounds and to progress others through pre-clinical and early development to address the unmet medical needs of patients and physicians. For more information, please visit the Company’s Web site at www.biocryst.com.
|
Company: |
BioCryst Pharmaceuticals | |
|
Headquarters Address: |
2190 Parkway Lake Drive | |
| Birmingham, AL 35244 | ||
|
Main Telephone: |
205-444-4600 | |
|
Website: |
||
|
Ticker: |
NASDAQ: BCRX |
|
|
Type of Organization: |
Public | |
|
Industry: |
Biotechnology | |
|
Key Executives: |
CEO: Jon Stonehouse |
|
|
CFO: Stuart Grant |
||
|
Chief Medical Officer: William Sheridan |
||
|
Investor Relations |
||
|
Contact: |
Robert Bennett | |
|
Phone: |
919-859-7910 | |
|
Email: |
||
KEYWORDS: United States North America North Carolina
INDUSTRY KEYWORDS: Health Pharmaceutical
MEDIA:
| Logo |